CNX-2006 is primarily used in the development of targeted cancer therapies. It functions as a selective inhibitor of specific kinases involved in tumor growth and progression, making it a valuable candidate in oncology research. Its application is particularly notable in studies focusing on solid tumors, where it demonstrates the ability to suppress signaling pathways that drive cell proliferation and survival. Due to its optimized pharmacokinetic profile, CNX-2006 is also being evaluated for its potential in overcoming resistance to existing treatments, offering a promising approach for combination therapies in advanced cancers.